Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + axitinib + stereotactic ablative body radiotherapy
- Development stage
- Unknown
- Lead developer
- Li Ning
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This therapeutic regimen is a triple-modality combination being investigated for the treatment of recurrent or metastatic renal cell carcinoma (RCC). It consists of **toripalimab**, a fully human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to block its interaction with PD-L1 and PD-L2, thereby restoring T-cell anti-tumor activity; **axitinib**, a potent and selective small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3) that inhibits tumor angiogenesis; and **stereotactic ablative body radiotherapy (SABR)**, a non-invasive technique that delivers high doses of ionizing radiation to specific tumor sites. The combination aims to leverage the synergistic effects of local tumor destruction and potential systemic immune activation (abscopal effect) induced by SABR, the anti-angiogenic properties of axitinib, and the immune checkpoint inhibition of toripalimab. This specific regimen is currently being evaluated in a Phase 2 clinical trial led by Peking University First Hospital.
- Brand names
- TuoyiInlyta
- Other names
- toripalimab-Peking University First Hospital-renal cell carcinomaSABR + Axitinib + ToripalimabToripalimab + Axitinib + SABR
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + axitinib + stereotactic ablative body radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + axitinib + stereotactic ablative body radiotherapy.